Search results
We have invested more than $2 billion since 2001 in Canadian pharmaceutical and vaccines Research & Development (R&D), with over 109 million in 2022 alone. In 2022, we invested over $21 million into 54 active clinical trials across Canada involving 3,700 active subjects.
This website is intended for visitors looking for information on GSK Canada. Other market sites can be reached by visiting our location selector . © 2001-2024 GSK plc.
If you are a healthcare professional, you can access more product information on our GSKPro website. Visit GSKPro for more information. The full A-Z list of our products available in Canada.
Jul 15, 2022 · Date modified: 2022-07-15. The Honourable Jean-Yves Duclos, Minister of Health, and the Honourable Filomena Tassi, Minister of Public Services and Procurement, announced that the Government of Canada has signed a new contract with GlaxoSmithKline to support sustained influenza pandemic readiness.
Sep 22, 2020 · Agreements relate to vaccine candidate using Sanofi’s recombinant protein-based technology and GSK’s pandemic adjuvant. Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine | GSK
Issued: London UK. GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged 50 years or older. [i] Shingrix is a non-live, recombinant subunit adjuvanted vaccine given intramuscularly in two doses.
Oct 4, 2021 · Oct 4 (Reuters) - London-based drugmaker GlaxoSmithKline PLC (GSK.L) said on Monday it signed a deal to supply 10,000 doses of its COVID-19 monoclonal antibody therapy to the Canadian government.
